Sanara MedTech Inc. Reports Strong FY2025 Results, Reaffirms 2026 Guidance – Key Details for Investors

Overview

Sanara MedTech Inc. (Nasdaq: SMTI), a medical technology company specializing in transformative surgical solutions, has released its unaudited financial results for the fourth quarter and full year ended December 31, 2025. The company also reaffirmed its financial guidance for 2026, signaling continued growth and operational focus. This report contains several key developments and financial metrics that are highly relevant for shareholders and may significantly impact the company’s share price.

Key Financial Highlights

• Fourth Quarter 2025:
  • Net revenue increased 5% year-over-year to \$27.5 million (Q4 2024: \$26.3 million).
  • Excluding \$1.8 million in extraordinary BIASURGE sales in Q4 2024 (due to supply chain disruptions from Hurricane Helene), net revenue growth for Q4 2025 was a robust 13%.
  • Adjusted EBITDA rose to \$4.7 million (Q4 2024: \$4.1 million).
  • Gross profit margin expanded to 93% (Q4 2024: 91%).
  • Net loss from continuing operations was \$1.1 million, compared to net income of \$0.9 million in Q4 2024. Including discontinued operations, net loss was \$1.6 million (Q4 2024: \$1.7 million).
  • Operating expenses increased 13% to \$24.6 million, mainly due to a \$1.8 million asset impairment charge and a 130% increase in R&D expenditures.
  • Net cash from operating activities surged to \$3.9 million (Q4 2024: \$0.9 million).
• Full Year 2025:
  • Net revenue rose 19% to \$103.1 million (2024: \$86.7 million).
  • Excluding extraordinary BIASURGE sales in Q4 2024, full-year net revenue grew 22%.
  • Adjusted EBITDA more than doubled to \$17.0 million (2024: \$9.1 million).
  • Net loss from continuing operations narrowed to \$0.4 million (2024: \$1.9 million).
  • Net cash from operating activities was \$6.8 million, a huge improvement compared to \$23.8 thousand used in 2024.
  • Net loss including discontinued operations ballooned to \$37.6 million, primarily due to a \$26.5 million non-cash asset impairment charge related to discontinued Tissue Health Plus (THP) operations.
  • Cash at year-end was \$16.6 million; long-term debt increased to \$46.0 million (2024: \$30.7 million).
  • Gross margin for the year remained strong at 93%.

Operational and Strategic Updates

• Strategic Realignment:
  • Sanara completed a realignment to focus exclusively on the surgical market. Discontinued operations related to THP resulted in significant impairment charges, but the company now operates as a “pure play surgical business” with a clear direction and margin profile.
• Product & Market Expansion:
  • On December 10, 2025, Sanara updated shareholders on its strategic alliance with Biomimetic Innovations Ltd (BMI), reaffirming plans to launch the OsStic Synthetic Injectable Structural Bio-Adhesive in the U.S. by Q1 2027, pending FDA clearance. This product targets reduction and provisional fixation treatment for over 100,000 peri-articular fractures annually.
  • On January 7, 2026, BIASURGE received an Innovative Technology contract from Vizient Inc., the largest provider-driven healthcare performance improvement company in the U.S. This contract, effective January 1, 2026, gives Vizient’s extensive customer network access to BIASURGE at contracted pricing and could materially increase sales volume.
  • On March 11, 2026, a peer-reviewed study in the Journal of Medical Economics demonstrated cost savings and improved outcomes with CellerateRX Surgical Powder as an adjunct for high-risk spinal surgery patients.

2026 Financial Guidance

• Sanara reaffirmed its 2026 guidance, projecting net revenue between \$116 million and \$121 million, representing 13% to 17% growth over 2025.

Management Commentary

Seth Yon, President and CEO, highlighted strong commercial execution, distributor expansion, and surgeon engagement as drivers of 2025’s results. The company is committed to sustaining growth, expanding market access, and investing in R&D for both current products and pipeline development. Operating leverage and gross margin improvements are expected to support profitability and cash generation in coming years.

Balance Sheet Snapshot

• Cash: \$16.6 million (2025), \$15.9 million (2024).
• Long-term debt: \$46.0 million (2025), \$30.7 million (2024).
• Shareholders’ equity: \$5.9 million (2025), \$38.9 million (2024). The drop is mainly due to the impairment charge from discontinued operations.

Additional Details for Investors

• Sanara’s strategic focus on the surgical market and margin profile may enhance long-term shareholder value.
• The Vizient contract for BIASURGE could be a significant sales catalyst and a potential share price mover.
• FDA clearance and commercial launch of OsStic in 2027 would open new market opportunities.
• Impairment charges and discontinued operations have affected reported net loss, but underlying business is profitable and generating strong cash flows.
• Adjusted EBITDA and net revenue (excluding extraordinary items) show strong core business performance.

Risks and Forward-Looking Statements

• Forward-looking statements may involve risks related to product development, regulatory approvals, market acceptance, competition, economic conditions, and integration of acquisitions.
• Investors should monitor debt levels, cash flow, and any developments related to FDA approvals and Vizient contract performance.

Conclusion

Sanara MedTech’s FY2025 results, strategic realignment, expanded market access, and reaffirmed 2026 guidance indicate positive momentum. The Vizient contract for BIASURGE and anticipated OsStic launch are potentially price-sensitive catalysts. Shareholders should watch for execution on these fronts and monitor cash generation and debt management.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All financial data is based on unaudited reports and forward-looking statements are subject to risks and uncertainties. Investors should conduct their own research and consult with professional advisers before making investment decisions.

View Sanara MedTech Inc. Historical chart here